Search Results 1621-1630 of 15616 for sunwin.men
Both females and male subjects with female partners of child-bearing potential must agree to use a highly effective method of contraception for 2 weeks ...
While on study drug and for 3 months following the last dose of study drug, a male subject must agree to use an adequate contraception method as deemed ...
Inability to refrain from smoking on trial days. Male patients who do not agree to minimize the risk of female partners becoming pregnant from first dosing ...
Male or female. Age 18 years or above at the time of signing the informed consent. Have an established diagnosis of ATTR-CM (wild-type ATTR [ATTRwt] or ...
Participation eligibility · Pregnant women; · Nursing women; · Men or women of child bearing potential (WCBP) who are unwilling to employ effective contraception.
Pregnancy or women of childbearing potential and men who are sexually active and not willing/able to use medically acceptable forms of contraception; Patents ...
- Safety Lead-In = Male/female ≥ 18 years old - Phase 3 and Cohort 3: Male/female ≥ 16 years old (where permitted locally) - Histologically or ...
This protocol is being designed to offer testicular tissue cryopreservation to male pediatric patients (0-17 years of age) with fertility threatening ...
Male or female. Subject has documented paroxysmal, or persistent atrial fibrillation (AF) with a history of less than one-year duration. Must be in AF at ...
Proton beam radiation therapy is one of the treatments for men with prostate cancer who have localized disease. The benefit of the combination with androgen ...
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Hurry to 3X your gift’s impact on cancer research and care!